Phenoxodiol (Haginin E)

Catalog No.S9634 Synonyms: Idronoxil, Dehydroequol, NV 06, PXD

For research use only.

Phenoxodiol (Haginin E, Idronoxil, Dehydroequol, NV 06, PXD) is an isoflavone analog with antineoplastic activity that activates the caspase system, inhibits XIAP (X-linked inhibitor of apoptosis), and disrupts FLICE inhibitory protein (FLIP) expression, resulting in tumor cell apoptosis. Phenoxodiol also inhibits DNA topoisomerase II.

Phenoxodiol (Haginin E) Chemical Structure

CAS No. 81267-65-4

Selleck's Phenoxodiol (Haginin E) has been cited by 1 Publication

Purity & Quality Control

Choose Selective Caspase Inhibitors

Other Caspase Products

Biological Activity

Description Phenoxodiol (Haginin E, Idronoxil, Dehydroequol, NV 06, PXD) is an isoflavone analog with antineoplastic activity that activates the caspase system, inhibits XIAP (X-linked inhibitor of apoptosis), and disrupts FLICE inhibitory protein (FLIP) expression, resulting in tumor cell apoptosis. Phenoxodiol also inhibits DNA topoisomerase II.
Targets
Caspase [1] XIAP [1] FLIP [1] Topo II [2]
In vitro

Primary ovarian cancer cells, isolated from ascitic fluids of ovarian cancer patients, resistant to conventional chemotherapy, undergo apoptosis following phenoxodiol treatment. This effect is dependent upon the activation of the caspase system, inhibiting XIAP, an inhibitor of apoptosis, and disrupting FLICE inhibitory protein (FLIP) expression through the Akt signal transduction pathway. Phenoxodiol is an efficient inducer of cell death in ovarian cancer cells and sensitizes the cancer cells to Fas-mediated apoptosis.[1]

In vivo

In an in vivo colon cancer model, Balb/C mice administered low-dose Phenoxodiol (PXD), exhibits significantly reduced tumour growth rates and prolonged survival (in 40% of the animals).[4]

Protocol (from reference)

Cell Research:

[1]

  • Cell lines: primary ovarian cancer cells
  • Concentrations: 0.1 μg/ml, 1 μg/ml, 10 μg/ml
  • Incubation Time: 24 h
  • Method:

    Cells are treated in the presence or absence of 500 ng/ml Fas-antibody in Optimem for 24 h or with 0.1, 1 or 10 μg/ml phenoxodiol, NV03, NV05 or NV07 in Optimem for 24 h. For treatment with phenoxodiol and caspase inhibitors, 10 μg/ml phenoxodiol is used alone, or in combination with 20 μM general caspase-inhibitor Z-VADFMK and incubated for 24 h.

Animal Research:

[4]

  • Animal Models: 7–8-week-old female Balb/C mice
  • Dosages: 10 mg/kg, 20 mg/kg
  • Administration: IP

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 240.25
Formula

C15H12O3

CAS No. 81267-65-4
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles C1C(=CC2=C(O1)C=C(C=C2)O)C3=CC=C(C=C3)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05100628 Not yet recruiting Drug: NOX66|Drug: Doxorubicin Metastatic Soft-tissue Sarcoma Noxopharm Limited November 15 2021 Phase 1
NCT04957290 Recruiting Drug: NOX66|Radiation: EBRT Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors Noxopharm Limited October 25 2021 Phase 1|Phase 2
NCT00557037 Completed Drug: Phenoxodiol Prostate Cancer MEI Pharma Inc. November 2007 Phase 2
NCT00878800 Completed Drug: PXD101|Drug: Doxorubicin Dose Escalation: Solid Tumors|MTD: Soft Tissue Sarcomas Onxeo|Spectrum Pharmaceuticals Inc December 2006 Phase 1|Phase 2

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Phenoxodiol (Haginin E) | Phenoxodiol (Haginin E) supplier | purchase Phenoxodiol (Haginin E) | Phenoxodiol (Haginin E) cost | Phenoxodiol (Haginin E) manufacturer | order Phenoxodiol (Haginin E) | Phenoxodiol (Haginin E) distributor